Introduction
Materials and methods
Patients
MMP-8 and TIMP-1 serum concentrations
HPV DNA genotyping
Immunohistochemistry of p16, MMP-8, and TIMP-1
Immunoscoring
Statistical analysis
Results
Patient characteristics
Variable | HPV + | % | HPV − | % | p-value |
---|---|---|---|---|---|
Number of patients | 53 | 58.1 | 37 | 41.9 | |
Mean age at diagnosis | 61.6 | 62.2 | 0.755 | ||
Sex
| |||||
Male | 43 | 81.1 | 23 | 62.2 | |
Female | 10 | 11.1 | 14 | 37.8 | 0.045* |
Smoking
| |||||
Non-smoker | 20 | 37.7 | 8 | 21.6 | |
Ex-smoker | 24 | 45.3 | 6 | 16.2 | |
Current smoker | 9 | 17.0 | 23 | 62.2 | < 0.001** |
Heavy alcohol use
| |||||
Never | 28 | 70.0 | 15 | 44.1 | |
Former | 2 | 5.0 | 8 | 23.5 | |
Current | 10 | 25.0 | 11 | 32.4 | 0.028* |
T class
| |||||
T1–T2 | 35 | 66.0 | 23 | 62.2 | |
T3–T4 | 18 | ||||
T2 | 34.0 | 14 | 37.8 | 0.705 | |
N class
| |||||
N0–N1 | 50 | 94.3 | 24 | 64.9 | |
N2–N3 | 3 | 5.7 | 13 | 35.1 | < 0.001** |
Stage
| |||||
I-II | 44 | 83 | 19 | 51.4 | |
III-IV | 9 | 17.0 | 18 | 48.6 | 0.001** |
Grade
| |||||
I | 1 | 1.9 | 2 | 5.4 | |
II | 3 | 5.7 | 12 | 32.4 | |
III | 49 | 92.5 | 23 | 62.2 | < 0.001** |
Treatment
| |||||
(C)RT | 39 | 73.6 | 23 | 62.2 | |
Sx +− (C)RT | 14 | 26.4 | 14 | 37.8 | 0.249 |
TIMP-1 serum level (pM) | 8206 | 7869 | 0.879 | ||
MMP-8 serum level (pM) | 762 | 844 | 0.253 | ||
TIMP-1 immunoexpression | |||||
0 | 7 | 13.5 | 6 | 18.8 | |
1 | 30 | 57.7 | 20 | 62.4 | |
2 | 15 | 28.8 | 6 | 18.8 | |
3 | 0 | 0 | 0 | 0 | 0.541 |
MMP-8 immunoexpression | |||||
0 | 3 | 5.9 | 4 | 12.5 | |
1 | 34 | 66.7 | 13 | 40.6 | |
2 | 13 | 25.5 | 11 | 34.4 | |
3 | 1 | 2.0 | 4 | 4.8 | 0.052 |
TIMP-1 is immunoexpressed in the majority of the tumors and MMP-8 in the surrounding cells
TIMP-1 serum levels are several fold higher compared with MMP-8 serum levels
TIMP-1, MMP-8, and survival
Univariate analysis | Multivariate analysis | Multivariate analysis | Multivariate analysis | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
All patients | All patients | HPV-positive patients | HPV-negative patients | |||||||||
HR | 95% CI | p-value | HR | 95% CI | p-value | HR | 95% CI | p-value | HR | 95% CI | p-value | |
Age | 1.1 | 1.0–1.1 | 0.003* | 1.1 | 1.0–1.1 | 0.004** | 1.1 | 0.9–1.2 | 0.119 | 1.0 | 0.9–1.1 | 0.249 |
Sex
| ||||||||||||
Female versus male | 1.4 | 0.6–3.3 | 0.499 | |||||||||
Smoking
| 0.003* | 0.008** | 0.016* | 0.399 | ||||||||
Ex-smoker versus never | 1.3 | 0.3–5.8 | 0.734 | 2.0 | 0.4–9.7 | 0.380 | 3.0 | 0.3–30.0 | 0.347 | 2.7 | 0.2–35.4 | 0.451 |
Current versus never | 5.5 | 1.6–18.9 | 0.007* | 6.7 | 1.8–24.4 | 0.004** | 14.5 | 1.7–127.6 | 0.016* | 3.1 | 0.6–16.6 | 0.176 |
T class
| ||||||||||||
T3–T4 versus T1–T2 | 1.3 | 0.6–2.9 | 0.578 | |||||||||
N class
| ||||||||||||
N2–N3 versus N0–N1 | 1.9 | 0.8–4.9 | 0.166 | |||||||||
Stage
| ||||||||||||
III–IV versus I–II | 3.4 | 1.5–7.8 | 0.004* | 2.4 | 0.9–5.9 | 0.068 | 1.7 | 0.3–10.5 | 0.562 | 8.7 | 1.5–50.6 | 0.017* |
Treatment
| ||||||||||||
Sx +− (C)RT versus (C)RT | 1.7 | 0.7–3.8 | 0.243 | |||||||||
HPV
| ||||||||||||
HPV − versus HPV + | 2.6 | 1.1–6.1 | 0.024* | 1.1 | 0.4–3.1 | 0.810 | ||||||
TIMP-1 serum level | 2.7 | 1.1–6.9 | 0.037* | 3.6 | 1.1–12.0 | 0.039* | 1.1 | 0.1–12.1 | 0.958 | 14.7 | 1.8–117.4 | 0.011* |
MMP-8 serum level | 1.1 | 0.66–1.8 | 0.739 | |||||||||
TIMP-1 immunoexpression | ||||||||||||
2–3 versus 0–1 | 1.5 | 0.6–3.8 | 0.340 | |||||||||
MMP-8 immunoexpression | ||||||||||||
2–3 versus 0–1 | 1.5 | 0.6–3.6 | 0.360 |